See more : PT Hetzer Medical Indonesia Tbk (MEDS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of ANI Pharmaceuticals, Inc. (ANIP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANI Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- AlerisLife Inc. (ALR) Income Statement Analysis – Financial Results
- Pacton Gold Inc. (PAC.V) Income Statement Analysis – Financial Results
- JSC National Atomic Company Kazatomprom (KAP.L) Income Statement Analysis – Financial Results
- ASA International Group PLC (ASAI.L) Income Statement Analysis – Financial Results
- The Supreme Industries Limited (SUPREMEIND.BO) Income Statement Analysis – Financial Results
ANI Pharmaceuticals, Inc. (ANIP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.anipharmaceuticals.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 486.82M | 316.39M | 216.14M | 208.48M | 206.55M | 201.58M | 176.84M | 128.62M | 76.32M | 55.97M | 30.08M | 2.30M | 435.16K | 2.47M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 2.00 | 1.00 | 123.06K |
| Cost of Revenue | 181.51M | 138.79M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M | 12.69M | 11.47M | 9.97M | 9.17M | 50.00K | 268.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -24.29K | 0.00 | 0.00 |
| Gross Profit | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M | 63.63M | 44.50M | 20.11M | -6.87M | 385.16K | 2.21M | 1.26M | 3.78M | 493.05K | 14.44M | 258.35K | 77.89K | 65.49K | 2.83M | 1.75M | 24.29K | 1.00 | 123.06K |
| Gross Profit Ratio | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% | 66.84% | -298.44% | 88.51% | 89.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,214,600.00% | 100.00% | 100.00% |
| Research & Development | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M | 2.87M | 2.68M | 1.71M | 16.89M | 44.18M | 39.71M | 13.68M | 15.79M | 4.75M | 3.86M | 6.41M | 9.16M | 3.69M | 4.79M | 2.14M | 1.89M | 660.59K | 1.40M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M | 21.16M | 17.94M | 16.39M | 8.23M | 6.98M | 5.94M | 5.67M | 5.96M | 4.33M | 7.03M | 3.05M | 3.08M | 2.33M | 1.77M | 2.30M | 1.68M | 853.39K | 1.11M |
| Other Expenses | 62.35M | 56.97M | 48.03M | 55.90M | 51.32M | -550.00K | 55.00K | -74.00K | 41.00K | 160.00K | -305.00K | 353.95K | 148.24K | 167.99K | 20.33M | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 92.56K | 122.79K | 90.97K | 269.70K |
| Operating Expenses | 258.33M | 203.33M | 143.70M | 136.89M | 126.97M | 93.19M | 68.58M | 53.08M | 30.93M | 24.49M | 19.21M | 25.47M | 51.31M | 45.81M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.69M | 1.60M | 2.78M |
| Cost & Expenses | 439.85M | 342.12M | 244.31M | 224.05M | 190.12M | 166.22M | 147.61M | 101.86M | 43.62M | 35.96M | 29.18M | 25.47M | 51.36M | 46.08M | 39.68M | 21.79M | 9.17M | 11.00M | 9.56M | 12.34M | 6.11M | 6.64M | 4.53M | 3.66M | 1.60M | 2.78M |
| Interest Income | 0.00 | 28.05M | 11.92M | 9.45M | 12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.54K | 8.33K | 12.67K | 11.65K | 588.46K | 1.10M | 428.34K | 401.19K | 250.42K | 86.59K | 63.79K | 174.42K | 227.72K | 0.00 | 0.00 |
| Interest Expense | 26.94M | 28.05M | 11.92M | 9.45M | 12.97M | 14.76M | 12.04M | 11.33M | 11.01M | 787.00K | 467.00K | 348.02K | 681.57K | 688.08K | 147.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 59.79M | 56.97M | 47.25M | 44.64M | 44.61M | 33.74M | 27.93M | 22.34M | 6.90M | 3.88M | 1.11M | 258.95K | 148.24K | 167.99K | 137.28K | 43.14K | 89.82K | 117.78K | 100.94K | 101.94K | 92.93K | 92.10K | 110.56K | 122.79K | 90.97K | 139.77K |
| EBITDA | 106.60M | 48.07M | -1.68M | 29.07M | 60.74M | 69.10M | 57.16M | 56.31M | 39.64M | 24.04M | 7.51M | -27.23M | -50.78M | -45.34M | -47.24M | -17.38M | -7.49M | 3.56M | -9.55M | -11.91M | -5.95M | -3.72M | -2.68M | -3.31M | -1.51M | -2.52M |
| EBITDA Ratio | 21.90% | 10.09% | 6.82% | 13.71% | 29.44% | 34.01% | 32.35% | 38.12% | 51.94% | 42.96% | 5.66% | -995.51% | -11,667.01% | -1,678.41% | -2,330.70% | -475.31% | -1,742.13% | 32.10% | -3,271.24% | -15,618.58% | -9,089.41% | -131.22% | -153.10% | -177,106,050.00% | -151,397,600.00% | -2,047.48% |
| Operating Income | 46.97M | -25.06M | -32.51M | -16.06M | 16.35M | 35.36M | 28.33M | 20.08M | 32.70M | 20.01M | 898.00K | -23.17M | -50.93M | -43.61M | -38.43M | -18.01M | -8.68M | 3.44M | -9.30M | -12.27M | -6.05M | -3.81M | -2.79M | -3.66M | -1.60M | -2.66M |
| Operating Income Ratio | 9.65% | -7.92% | -15.04% | -7.71% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -1,007.14% | -11,703.01% | -1,762.50% | -3,054.36% | -476.45% | -1,760.34% | 23.82% | -3,600.61% | -15,749.47% | -9,231.29% | -134.47% | -159.43% | -183,245,550.00% | -160,494,100.00% | -2,161.05% |
| Total Other Income/Expenses | -27.10M | -27.38M | -16.27M | -9.95M | -13.19M | -15.31M | -11.98M | -11.40M | -10.97M | -627.00K | -772.00K | -5.60M | -681.67K | -2.59M | -9.10M | -17.41B | -7.58B | -1.08M | -348.81K | 250.42K | 86.59K | 0.00 | 174.42K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 19.87M | -62.67M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M | 21.73M | 19.38M | 126.00K | -27.84M | -51.61B | -46.20B | -47.53B | -17.43B | -7.58B | 2.79B | -9.65B | -12.02M | -5.96M | -3.81M | -2.61M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 4.08% | -19.81% | -25.94% | -12.45% | 1.53% | 9.95% | 9.24% | 6.75% | 28.48% | 34.62% | 0.42% | -1,210.03% | -11,859,661.73% | -1,867,089.37% | -3,777,879.80% | -460,882.47% | -1,538,256.46% | 19,331.99% | -3,735,629.43% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M | 6.36M | -9.37M | 20.00K | -121.79K | 681.67K | 2.59M | 9.10M | -17.41B | -7.58B | 648.49K | 348.81K | 0.00 | 0.00 | 0.00 | 0.00 | -227.72K | -198.68K | 0.00 |
| Net Income | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M | 15.38M | 28.75M | 301.00K | -27.72M | -51.61M | -46.20M | -47.53M | -17.43M | -7.58M | 2.79M | -9.65M | -12.02M | -5.96M | -3.81M | -2.61M | -3.44M | -1.41M | -2.66M |
| Net Income Ratio | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1.00% | -1,204.73% | -11,859.66% | -1,867.09% | -3,777.88% | -460.88% | -1,538.26% | 19.33% | -3,735.63% | -15,427.94% | -9,099.08% | -134.47% | -149.44% | -171,859,750.00% | -140,625,900.00% | -2,161.05% |
| EPS | 0.95 | -2.95 | -3.38 | -1.88 | 0.51 | 1.33 | -0.09 | 0.34 | 1.34 | 2.61 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| EPS Diluted | 0.94 | -2.95 | -3.38 | -1.88 | 0.50 | 1.32 | -0.09 | 0.34 | 1.32 | 2.59 | -0.92 | -7.64 | -18.88 | -25.23 | -50.39 | -22.97 | -10.71 | 4.68 | -17.92 | -25.23 | -19.44 | -18.28 | -14.50 | -21.51 | -10.24 | -27.47 |
| Weighted Avg Shares Out | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 588.64K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
| Weighted Avg Shares Out (Dil) | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5.07M | 3.63M | 2.73M | 1.83M | 943.11K | 758.54K | 707.93K | 596.78K | 538.67K | 476.26K | 306.63K | 208.42K | 180.15K | 159.82K | 137.29K | 96.83K |
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company...
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024
Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable...
Source: https://incomestatements.info
Category: Stock Reports